{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:55:36Z","timestamp":1759514136258,"version":"3.41.2"},"reference-count":79,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443133480"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.ircmb.2023.10.004","type":"book-chapter","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T15:35:51Z","timestamp":1697729751000},"page":"25-46","source":"Crossref","is-referenced-by-count":1,"title":["Radiation for inflammatory breast cancer: Updates"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2023.10.004_bib1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/cncr.28550","article-title":"Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer","volume":"120","author":"Akay","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdt496","article-title":"Gene expression profiles of inflammatory breast cancer: Correlation with response to neoadjuvant chemotherapy and metastasis-free survival","volume":"25","author":"Bertucci","year":"2014","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clbc.2016.02.004","article-title":"Inflammatory TNBC breast cancer: Demography and clinical outcome in a large cohort of patients with TNBC","volume":"16","author":"Biswas","year":"2016","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib5","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1084\/jem.20130762","article-title":"Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy","volume":"210","author":"Bos","year":"2013","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2012.01.008","article-title":"Effect of preoperative rescue concomitant FUN\/XUN-based chemo-radiotherapy for neoadjuvant chemotherapy-refractory breast cancer","volume":"103","author":"Bourgier","year":"2012","journal-title":"Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/BD-2006-22109","article-title":"Inflammatory breast cancer: Current concepts in local management","volume":"22","author":"Bristol","year":"2005","journal-title":"Breast Disease"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijrobp.2008.01.039","article-title":"Locoregional treatment outcomes after multimodality management of inflammatory breast cancer","volume":"72","author":"Bristol","year":"2008","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ijrobp.2014.01.054","article-title":"Once-daily radiation therapy for inflammatory breast cancer","volume":"89","author":"Brown","year":"2014","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5152\/ejbh.2018.4170","article-title":"The impact of subtype distribution in inflammatory breast cancer outcome","volume":"14","author":"\u00c7akar","year":"2018","journal-title":"European Journal of Breast Health"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djh005","article-title":"Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361","volume":"96","author":"Calabrese","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00259-013-2506-8","article-title":"(18)F-FDG PET\/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy","volume":"40","author":"Carkaci","year":"2013","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib13","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2967\/jnumed.115.158287","article-title":"18F-FDG PET\/CT to predict response to neoadjuvant chemotherapy and prognosis in inflammatory breast cancer","volume":"56","author":"Champion","year":"2015","journal-title":"Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s00259-013-2405-z","article-title":"\u00b9\u2078F-FDG PET\/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer","volume":"40","author":"Champion","year":"2013","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib15","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2366::AID-CNCR10>3.0.CO;2-N","article-title":"Inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992","volume":"82","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1242\/jcs.03348","article-title":"Wnt\/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line","volume":"120","author":"Chen","year":"2007","journal-title":"Journal of Cell Science"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10434-999-0249-3","article-title":"Beyond palliative mastectomy in inflammatory breast cancer--A reassessment of margin status","volume":"6","author":"Curcio","year":"1999","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib19","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.ijrobp.2009.06.042","article-title":"Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era","volume":"77","author":"Damast","year":"2010","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/annonc\/mdr319","article-title":"Identifying factors that impact survival among women with inflammatory breast cancer","volume":"23","author":"Dawood","year":"2012","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib21","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib23","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/jco.2004.22.90140.3559","article-title":"Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer","volume":"22","author":"Dunst","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0002-9610(91)90076-P","article-title":"Long-term results of a combined modality approach in treating inflammatory carcinoma of the breast","volume":"162","author":"Elias","year":"1991","journal-title":"American Journal of Surgery"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/01.coc.0000245475.41324.6d","article-title":"A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer","volume":"30","author":"Gaui","year":"2007","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"Giuliano","year":"2016","journal-title":"Annals of Surgery"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1634\/theoncologist.12-8-904","article-title":"Trends for inflammatory breast cancer: Is survival improving?","volume":"12","author":"Gonzalez-Angulo","year":"2007","journal-title":"The Oncologist"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2010.02.013","article-title":"Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation","volume":"95","author":"Greenbaum","year":"2010","journal-title":"Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","article-title":"Mitotic progression following DNA damage enables pattern recognition within micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jsurg.2011.10.016","article-title":"Lessons learned from an unusual case of inflammatory breast cancer","volume":"69","author":"Harrison","year":"2012","journal-title":"Journal of Surgical Education"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib34","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1586\/era.10.53","article-title":"Poly(ADP-ribosyl)ation polymerases: Mechanism and new target of anticancer therapy","volume":"10","author":"Heitz","year":"2010","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib35","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","article-title":"Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: The TBCRC 024 phase I multicenter study","volume":"36","author":"Jagsi","year":"2018","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2006.05.063","article-title":"Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer","volume":"66","author":"Krishnan","year":"2006","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1471-4906(01)01860-9","article-title":"Dendritic cells resurrect antigens from dead cells","volume":"22","author":"Larsson","year":"2001","journal-title":"Trends in Immunology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib39","doi-asserted-by":"crossref","first-page":"W769","DOI":"10.2214\/AJR.10.6157","article-title":"MRI features of inflammatory breast cancer","volume":"197","author":"Le-Petross","year":"2011","journal-title":"AJR. American Journal of Roentgenology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","article-title":"PARP inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee","year":"2014","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib41","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0360-3016(00)00561-7","article-title":"Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence","volume":"47","author":"Liao","year":"2000","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2017.06.014","article-title":"Preoperative breast radiation therapy: Indications and perspectives","volume":"82","author":"Lightowlers","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib43","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib44","unstructured":"NCCN. (2023). Clinical practice guidelines in oncology. Breast cancer, version 4. 2023."},{"key":"10.1016\/bs.ircmb.2023.10.004_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010107","article-title":"Radiotherapy in the management of non-metastatic inflammatory breast cancers: A retrospective observational study","volume":"14","author":"Nicaise","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrclinonc.2013.182","article-title":"Latest biopsy approach for suspected metastases in patients with breast cancer","volume":"10","author":"Niikura","year":"2013","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib47","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ijrobp.2014.05.201","article-title":"PD-1 blockade enhances radiation therapy-induced abscopal effect","volume":"90","author":"Park","year":"2014","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib48","doi-asserted-by":"crossref","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Science Signaling"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib49","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/jnci\/djj495","article-title":"The response of CD24(-\/low)\/CD44+ breast cancer-initiating cells to radiation","volume":"98","author":"Phillips","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib50","doi-asserted-by":"crossref","first-page":"8610","DOI":"10.1245\/s10434-021-10148-1","article-title":"Contralateral axillary metastasis in patients with inflammatory breast cancer","volume":"28","author":"Postlewait","year":"2021","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib51","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijrobp.2012.01.030","article-title":"Modern outcomes of inflammatory breast cancer","volume":"84","author":"Rehman","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib53","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5114\/pdia.2015.48069","article-title":"Carcinoma en cuirasse as an initial manifestation of inflammatory breast cancer","volume":"33","author":"Reich","year":"2016","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib54","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2014.55.1978","article-title":"Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: An analysis of treatment and survival trends from the National Cancer Database","volume":"32","author":"Rueth","year":"2014","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/BD-201020","article-title":"Primary breast carcinoma en cuirasse. A rare presentation of an aggressive malignancy and review of the literature","volume":"39","author":"Salemis","year":"2020","journal-title":"Breast Disease"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib56","first-page":"2948","article-title":"X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts","volume":"5","author":"Sawada","year":"1999","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib57","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib58","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib59","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): Novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ctrv.2012.04.001","article-title":"Management of inflammatory breast cancer: Focus on radiotherapy with an evidence-based approach","volume":"39","author":"Scotti","year":"2013","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib62","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1158\/1078-0432.CCR-05-1224","article-title":"The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks","volume":"11","author":"Smith","year":"2005","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib63","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.prro.2019.05.011","article-title":"Excellent locoregional control in inflammatory breast cancer with a personalized radiation therapy approach","volume":"9","author":"Stecklein","year":"2019","journal-title":"Practical Radiation Oncology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib64","unstructured":"SWOG. (2018). A phase II randomized trial of olaparib (NSC-747856) administered concurrently with radiotherapy versus radiotherapy alone for inflammatory breast cancer."},{"key":"10.1016\/bs.ircmb.2023.10.004_bib65","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/2193-1801-3-166","article-title":"Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation","volume":"3","author":"Takiar","year":"2014","journal-title":"Springerplus"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Current Opinion in Immunology"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib68","unstructured":"US Food and Drug Administration. (2021). FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer\u3009. Accessed May 8, 2023."},{"key":"10.1016\/bs.ircmb.2023.10.004_bib69","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib70","first-page":"122","article-title":"Carcinoma en cuirasse: A cutaneous clue for systemic malignancy","volume":"4","author":"Varghese","year":"2013","journal-title":"International Journal of Preventive Medicine"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib71","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ijrobp.2011.10.040","article-title":"Pretreatment staging positron emission tomography\/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs","volume":"83","author":"Walker","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib72","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1002\/cncr.34441","article-title":"Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer","volume":"128","author":"Warren","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib73","unstructured":"White, J., Tai, A., Arthur, D., Buchholz, T., MacDonald, S., Marks, L., ... Li, X. L. (n.d.). Breast cancer Atlas for radiation therapy planning: Consensus definitions."},{"key":"10.1016\/bs.ircmb.2023.10.004_bib74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1023\/B:CACO.0000024222.61114.18","article-title":"Population-based statistics for women diagnosed with inflammatory breast cancer (United States)","volume":"15","author":"Wingo","year":"2004","journal-title":"Cancer Causes & Control: CCC"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib75","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ijrobp.2014.05.004","article-title":"Postmastectomy radiation therapy for inflammatory breast cancer: Is more better?","volume":"89","author":"Woodward","year":"2014","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib76","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1073\/pnas.0606599104","article-title":"WNT\/beta-catenin mediates radiation resistance of mouse mammary progenitor cells","volume":"104","author":"Woodward","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib77","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ijrobp.2017.04.030","article-title":"A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer","volume":"99","author":"Woodward","year":"2017","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2217\/bmt.13.68","article-title":"Radiation therapy for inflammatory breast cancer: Technical considerations and diverse clinical scenarios","volume":"3","author":"Woodward","year":"2014","journal-title":"Breast Cancer Management"},{"key":"10.1016\/bs.ircmb.2023.10.004_bib79","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2353\/ajpath.2008.071214","article-title":"The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype","volume":"173","author":"Xiao","year":"2008","journal-title":"The American Journal of Pathology"}],"container-title":["International Review of Cell and Molecular Biology","Overview of Inflammatory Breast Cancer: Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823001624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823001624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:15:10Z","timestamp":1753715710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644823001624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443133480"],"references-count":79,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2023.10.004","relation":{},"ISSN":["1937-6448"],"issn-type":[{"type":"print","value":"1937-6448"}],"subject":[],"published":{"date-parts":[[2024]]}}}